Abstract:
Recent studies suggest that PEBP1 (also known as RKIP) and YY1, despite having distinct molecular functions, may interact and mutually influence each other\'s activity. They exhibit reciprocal control over each other\'s expression through regulatory loops, prompting the hypothesis that their interplay could be pivotal in cancer advancement and resistance to drugs. To delve into this interplay\'s functional characteristics, we conducted a comprehensive analysis using bioinformatics tools across a range of cancers. Our results confirm the association between elevated YY1 mRNA levels and varying survival outcomes in diverse tumors. Furthermore, we observed differing degrees of inhibitory or activating effects of these two genes in apoptosis, cell cycle, DNA damage, and other cancer pathways, along with correlations between their mRNA expression and immune infiltration. Additionally, YY1/PEBP1 expression and methylation displayed connections with genomic alterations across different cancer types. Notably, we uncovered links between the two genes and different indicators of immunosuppression, such as immune checkpoint blockade response and T-cell dysfunction/exclusion levels, across different patient groups. Overall, our findings underscore the significant role of the interplay between YY1 and PEBP1 in cancer progression, influencing genomic changes, tumor immunity, or the tumor microenvironment. Additionally, these two gene products appear to impact the sensitivity of anticancer drugs, opening new avenues for cancer therapy.
摘要:
最近的研究表明,PEBP1(也称为RKIP)和YY1,尽管具有不同的分子功能,可以相互作用,相互影响对方的活动。它们通过调节环表现出对彼此表达的相互控制,提出了一种假设,即它们的相互作用可能在癌症进展和对药物的耐药性中至关重要。为了深入研究这种相互作用的功能特征,我们使用生物信息学工具对一系列癌症进行了全面分析.我们的结果证实了YY1mRNA水平升高与不同肿瘤生存结果之间的关联。此外,我们观察到这两个基因在细胞凋亡中不同程度的抑制或激活作用,细胞周期,DNA损伤,和其他癌症通路,以及它们的mRNA表达与免疫浸润之间的相关性。此外,YY1/PEBP1表达和甲基化显示了与不同癌症类型的基因组改变的联系。值得注意的是,我们发现了这两个基因和不同的免疫抑制指标之间的联系,如免疫检查点阻断反应和T细胞功能障碍/排斥水平,跨越不同的患者群体。总的来说,我们的发现强调了YY1和PEBP1之间的相互作用在癌症进展中的重要作用,影响基因组变化,肿瘤免疫,或肿瘤微环境。此外,这两种基因产物似乎会影响抗癌药物的敏感性,为癌症治疗开辟新的途径.